GDM-1 Xenograft Model Service for AML

The GDM-1 cell line, established from a human acute myeloid leukemia (AML) patient, provides an exceptional and translationally validated in vivo platform for investigating the molecular pathology of myeloid malignancies and assessing the therapeutic efficacy of novel antileukemic candidates. As a leading pre-clinical contract research organization, Alfa Cytology offers an integrated, comprehensive GDM-1 Xenograft Model Service designed to deliver high-quality, reproducible datasets that effectively accelerate your AML drug discovery and development pipeline.

Overview of GDM-1 Xenograft Model for AML

The GDM-1 xenograft model represents a highly specialized and deeply characterized in vivo translational tool widely deployed in hematological malignancy research, specifically targeting AML. By transplanting human GDM-1 myeloblastoid cells into optimized immunodeficient mouse models, this system effectively recapitulates the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles characteristic of human leukemic progression.

Biologically, the GDM-1 model is highly valued for its stable engraftment parameters and robust cellular proliferation, providing pre-clinical investigators with a predictable and reliable experimental window to evaluate novel targeted therapeutics. This model maintains critical human myeloid molecular features, including specific cell-surface antigen expressions such as CD13, CD14, and CD33, alongside native intracellular signaling profiles that drive myeloblast expansion. Consequently, the GDM-1 platform is extensively utilized in global pre-clinical screening operations to determine the anti-leukemic potency of small-molecule inhibitors, targeted monoclonal antibodies, novel immunotherapies, and combination systemic chemotherapy regimens.

Fig 1. Translocation t(6;7) in GDM-1 juxtaposes MNX1 with the MYB/AHI1 locus. (Weichenhan D, et al., 2023)

Cell Line Information: GDM-1

The GDM-1 cell line was originally established from the peripheral blood of a patient diagnosed with AML. These cells grow as suspended cultures under standard in vitro parameters, maintaining a stable myeloblastoid phenotype and providing an excellent genetic proxy for modern hematological oncology studies.

Our Services

Workflow of GDM-1 Xenograft Model Construction

• Cell Culture & Quality Control: Human GDM-1 cells are expanded in vitro utilizing certified nutrient suspension media under optimized growth parameters. Mandatory STR authentication and mycoplasma clearance verification are completed prior to harvesting to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunocompromised mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase within a controlled facility to stabilize baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability GDM-1 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, leukemic progression is systematically monitored using high-precision flow cytometry to detect human CD45+ or specific myeloid markers in peripheral blood samples. Animal body weights, physical baselines, and clinical symptoms of leukemic burden are routinely cataloged.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts. This stratification step ensures balanced baseline systemic dimensions across all groups before customized therapeutic dosing regimens commence.

Fig 2. GDM-1 Xenograft Model Construction Workflow

Case Study - GDM-1 Xenograft Model Development

A pre-clinical validation study was conducted utilizing the GDM-1 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting myeloid cell survival pathways in AML. Following precision intravenous inoculation of human GDM-1 cells into immunodeficient mice, the animals demonstrated steady, systemic leukemic engraftment and a highly predictable disease progression across the study cohorts. Animals assigned to the active treatment group exhibited a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control group, confirming the model's high sensitivity and robust predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in cultivating and maintaining diverse hematological and myeloid lineages, offering highly reproducible in vivo translational platforms for complex leukemia studies.
• Rigorous Quality Control: Meticulous cell validation profiling and standardized operating workflows that minimize experimental variability across all development phases.
• Tailored Experimental Design: Highly flexible protocols that adjust to specific animal strain options, customized dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive flow cytometry metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing our GDM-1 platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.